NBIX at a glance
Neurocrine Biosciences Inc (NBIX, SEC CIK 914475) filed its latest 10-K annual report on February 11, 2026, a 10-Q quarterly report on July 31, 2026, an 8-K current report on September 28, 2026 and Form 4 insider filings as recently as September 15, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Neurocrine Biosciences Inc (NBIX) reported revenue of $2.9 billion (up 21.4% from FY2024) and net income of $478.6 million. Diluted EPS was $4.67.
- As of June 30, 2026, 38 institutional investment managers tracked by SignalX reported holding Neurocrine Biosciences Inc (NBIX) shares worth $8.8 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Boyer David W. on September 14, 2026 of 826 shares at $157.45 per share.
- In the last 90 days, NBIX insiders reported 0 open-market purchases ($0) and 7 open-market sales ($5.1M) on Form 4, a net sale of $5.1M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $2.9B
- +21.4% vs prior year
- Insiders · 90 days
- 0 buys · 7 sells
- Net −$5.1M
- 13F holders
- 38 funds
- $8.8B · −1 vs prior quarter
- Latest 10-Q
- Jul 31, 2026
- Quarterly report
SignalX for NBIX
Don't miss the next NBIX filing
- Alerts as it files. A push when NBIX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut NBIX, by share count.
- Ask anything. An AI agent that reads every NBIX filing and answers with sources.
NBIX alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Boyer David W. | Sell | Sep 14, 2026 | 826 | $157.45 |
| ABERNETHY MATT | Sell | Sep 14, 2026 | 2,311 | $157.20 |
| Boyer David W. | A | Sep 11, 2026 | 3,587 | - |
| BENEVICH ERIC | F | Sep 11, 2026 | 3,386 | $156.22 |
| Cooke Julie | A | Sep 11, 2026 | 3,587 | - |
| GORMAN KEVIN CHARLES | F | Sep 11, 2026 | 7,839 | $156.22 |
| Cooke Julie | F | Sep 11, 2026 | 1,936 | $156.22 |
| Delaet Ingrid | A | Sep 11, 2026 | 4,483 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $2.4B | $2.9B |
| Operating Income | - | $570.5M | $619.1M |
| Net Income | $249.7M | $341.3M | $478.6M |
| Op. Margin | - | 24.2% | 21.6% |
| Net Margin | - | 14.5% | 16.7% |
| Balance Sheet | |||
| Total Assets | $3.3B | $3.7B | $4.6B |
| Equity | - | $2.6B | $3.3B |
| ROE | - | 13.2% | 14.7% |
| Per Share | |||
| EPS | $2.47 | $3.29 | $4.67 |
| Cash Flow | |||
| Operating CF | - | $595.4M | $782.7M |
| CapEx | $28.3M | $38.2M | $34.0M |
Source: XBRL data in Neurocrine Biosciences Inc (NBIX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate NBIX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 38 | $8.79B |
| Q1 2026 | 39 | $6.90B |
| Q4 2025 | 36 | $6.85B |
| Q3 2025 | 37 | $7.76B |
| Q2 2025 | 34 | $6.39B |
| Q1 2025 | 36 | $3.46B |
| Q4 2024 | 32 | $3.98B |
| Q3 2024 | 28 | $2.01B |
- JPMorgan Chase & Co+956.6K (+18%)
- Invesco Ltd+721.3K (+203%)
- BlackRock+326.0K (+2%)
- Goldman Sachs Group+282.7K (+81%)
- Vanguard Portfolio Management LLC+247.7K (+5%)
- Millennium Management−1.24M (-99%)
- AQR Capital Management−1.12M (-23%)
- Two Sigma Investments−984.3K (-32%)
- D.E. Shaw & Co−83.6K (-94%)
- Renaissance Technologies LLC−83.0K (-3%)
- Marex Group plc−4.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 280 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
NBIX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
NBIX SEC filings: frequently asked questions
Are NBIX insiders buying or selling?
In the last 90 days, Neurocrine Biosciences Inc (NBIX) officers, directors and 10% owners reported no open-market purchases and 7 open-market sales worth $5.1 million by 6 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold NBIX stock?
As of June 30, 2026, the largest Neurocrine Biosciences Inc (NBIX) holders among the 13F filers tracked by SignalX were BlackRock ($2.3 billion), JPMorgan Chase & Co ($1.1 billion), Vanguard Portfolio Management LLC ($838.3 million), Vanguard Capital Management LLC ($766.0 million), State Street Corp ($739.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was NBIX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Neurocrine Biosciences Inc (NBIX) reported revenue of $2.9 billion (up 21.4% from FY2024) and net income of $478.6 million. Diluted EPS was $4.67. The figures come from the XBRL data in the 10-K.
What are the latest NBIX SEC filings?
Neurocrine Biosciences Inc (NBIX) filed its latest 10-K annual report on February 11, 2026, a 10-Q quarterly report on July 31, 2026, an 8-K current report on September 28, 2026 and a Form 4 insider filing on September 15, 2026.
What is NBIX's SEC CIK number?
Neurocrine Biosciences Inc (NBIX)'s SEC Central Index Key (CIK) is 914475. EDGAR lists every NBIX filing under that number.
Ask anything about NBIX
The research agent reads NBIX's filings, financials, insider trades and 13F holders, then answers with sources.